Compare Enveric Biosciences Inc (ENVB) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Illinois Tool Works Inc. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Illinois Tool Works Inc. trades at $263.26 (market cap $74.38B). The key difference: Illinois Tool Works Inc. is far larger — about 11118.1× Enveric Biosciences Inc's market cap, and Illinois Tool Works Inc. pays a 2.63% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Illinois Tool Works Inc. for 67 Days on average.
| ENVB | ITW | |
|---|---|---|
Market Cap | $6.69M | $74.38B |
Volume | 41,141 | 1,125,477 |
Sector | Health | Industrials |
52-Week High | $10.80 | $299.60 |
52-Week Low | $1.27 | $241.07 |
Typical Hold Time | 14 Days | 67 Days |
Enterprise Value | -$1.60M | $83.23B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
ITW trades at $264.71, down 0.91% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 19.39% net margins and 104.65% ROE, though valuation multiples appear elevated. Recent dividend increase to $1.72 reinforces its Dividend King status with 59 years of consecutive growth. Operating cash flow remains robust at $3.13B, supporting continued shareholder returns.
Outlook remains mixed with analyst consensus target of $280.14 offering 5.8% upside, but technical indicators signal near-term pressure. The company faces headwinds in automotive and foodservice segments while maintaining strong organic growth prospects. Debt levels have increased to 55.54% of assets, requiring monitoring amid rising interest rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
